Payment overview · 2025
General Payments
$879.90
46 reported records · 11 companies
Healthcare provider profile · identity verified
Robert Flowers, M D
Allopathic & Osteopathic Physicians|Family Medicine · BURKESVILLE, KY · NPI 1437188067
Verified facts
What the public records show
CMS Open Payments records show Robert Flowers, M D received $879.90 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rexulti, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $373.25 | 42.4% | 16 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $134.90 | 15.3% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $115.56 | 13.1% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.04 | 7.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.56 | 5.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.16 | 4.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.03 | 3.6% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $20.19 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.11 | 2.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.31 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.79 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $879.90 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $252.18 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $231.31 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $135.67 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $134.90 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $110.24 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $64.04 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 125 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
125 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
125 | 12 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Potassium Chloride | Potassium Chloride | 676 | 118 |
| Furosemide | Furosemide | 631 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 584 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 573 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 504 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 67 |
| Omeprazole | Omeprazole | 338 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 325 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 321 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 316 | 63 |
| Trazodone Hcl | Trazodone Hcl | 292 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 277 | 37 |
| Losartan Potassium | Losartan Potassium | 276 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 266 | 46 |
| Xarelto | Rivaroxaban | 240 | 27 |
| Famotidine | Famotidine | 236 | 42 |
| Eliquis | Apixaban | 227 | 32 |
| Donepezil Hcl | Donepezil Hcl | 212 | 34 |
| Gabapentin | Gabapentin | 203 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 36 |
| Metformin Hcl | Metformin Hcl | 196 | 36 |
| Spironolactone | Spironolactone | 192 | 36 |
| Lisinopril | Lisinopril | 177 | 37 |
| Lorazepam | Lorazepam | 172 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 169 | 27 |
| Mirtazapine | Mirtazapine | 167 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 162 | 26 |
| Baclofen | Baclofen | 161 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 159 | 42 |
| Carvedilol | Carvedilol | 156 | 30 |
| Januvia | Sitagliptin Phosphate | 153 | 25 |
| Atenolol | Atenolol | 149 | 22 |
| Finasteride | Finasteride | 147 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 28 |
| Buspirone Hcl | Buspirone Hcl | 139 | 26 |
| Cefdinir | Cefdinir | 138 | 91 |
| Sertraline Hcl | Sertraline Hcl | 136 | 27 |
| Fenofibrate | Fenofibrate | 134 | 23 |
| Clonidine Hcl | Clonidine Hcl | 133 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 133 | 54 |
| Meloxicam | Meloxicam | 131 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 22 |
| Rexulti | Brexpiprazole | 125 | 12 |
| Glimepiride | Glimepiride | 122 | 21 |
| Montelukast Sodium | Montelukast Sodium | 121 | 20 |
| Prednisone | Prednisone | 116 | 90 |
| Alprazolam | Alprazolam | 112 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 110 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 109 | 89 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 106 | 19 |
| Memantine Hcl | Memantine Hcl | 106 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 104 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 104 | 16 |
| Sucralfate | Sucralfate | 104 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 42 |
| Paroxetine Hcl | Paroxetine Hcl | 100 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 49 |
| Mupirocin | Mupirocin | 95 | 69 |
| Sodium Chloride | 0.9 % Sodium Chloride | 94 | 30 |
| Meclizine Hcl | Meclizine Hcl | 92 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 29 |
| Digoxin | Digoxin | 91 | 15 |
| Simvastatin | Simvastatin | 90 | 16 |
| Levetiracetam | Levetiracetam | 87 | 12 |
| Terazosin Hcl | Terazosin Hcl | 83 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 33 |
| Nystatin | Nystatin | 82 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 79 | 18 |
| Jardiance | Empagliflozin | 78 | 11 |
| Farxiga | Dapagliflozin Propanediol | 77 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 14 |
| Tramadol Hcl | Tramadol Hcl | 76 | 17 |
| Fentanyl | Fentanyl | 75 | suppressed |
| Bumetanide | Bumetanide | 74 | 18 |
| Colchicine | Colchicine | 73 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 73 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 13 |
| Entresto | Sacubitril/Valsartan | 68 | suppressed |
| Ibuprofen | Ibuprofen | 68 | 30 |
| Warfarin Sodium | Warfarin Sodium | 68 | suppressed |
| Ezetimibe | Ezetimibe | 67 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 67 | 43 |
| Risperidone | Risperidone | 65 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 64 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 63 | 28 |
| Doxepin Hcl | Doxepin Hcl | 62 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 13 |
| Enalapril Maleate | Enalapril Maleate | 58 | suppressed |
| Fluconazole | Fluconazole | 58 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Tradjenta | Linagliptin | 58 | suppressed |
| Glipizide | Glipizide | 56 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | 13 |
| Levofloxacin | Levofloxacin | 52 | 36 |
| Metformin Hcl Er | Metformin Hcl | 51 | suppressed |
| Roflumilast | Roflumilast | 51 | suppressed |
| Linzess | Linaclotide | 50 | 11 |
| Pregabalin | Pregabalin | 49 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 14 |
| Divalproex Sodium | Divalproex Sodium | 45 | suppressed |
| Lactulose | Lactulose | 45 | 17 |
| Ondansetron Odt | Ondansetron | 45 | 22 |
| Carbamazepine | Carbamazepine | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 40 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Naproxen | Naproxen | 42 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 42 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 40 | 23 |
| Allopurinol | Allopurinol | 39 | 14 |
| Promethazine Hcl | Promethazine Hcl | 39 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 28 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 36 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | 19 |
| Nitroglycerin | Nitroglycerin | 35 | 23 |
| Cilostazol | Cilostazol | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Daptomycin | Daptomycin | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Constulose | Lactulose | 29 | suppressed |
| Phenobarbital | Phenobarbital | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 27 |
| Niacin Er | Niacin | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 18 |
| Multaq | Dronedarone Hcl | 25 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Metronidazole | Metronidazole | 24 | 19 |
| Nateglinide | Nateglinide | 24 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 24 | 24 |
| Theophylline Er | Theophylline Anhydrous | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Brilinta | Ticagrelor | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Humulin R | Insulin Regular, Human | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 14 |
| Cimetidine | Cimetidine | 21 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 20 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | 13 |
| Novofine 32 | Pen Needle, Diabetic | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Ertapenem | Ertapenem Sodium | 17 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 11 |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Ceftazidime | Ceftazidime | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Zafirlukast | Zafirlukast | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Zosyn | Piperacillin-Tazo-Dextrose,iso | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $879.90 · 46 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, INJECTAFER, Ozempic, PROLIA, REXULTI, Rybelsus, VERQUVO, VOQUEZNA, Wegovy, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error